Scinai Immunotherapeutics (NASDAQ:SCNI – Get Free Report) released its quarterly earnings results on Wednesday. The company reported $0.94 earnings per share (EPS) for the quarter, Zacks reports.
Scinai Immunotherapeutics Price Performance
Scinai Immunotherapeutics stock opened at $0.32 on Wednesday. The firm has a fifty day moving average of $0.54 and a 200-day moving average of $0.74. Scinai Immunotherapeutics has a 52-week low of $0.31 and a 52-week high of $3.48. The company has a quick ratio of 1.30, a current ratio of 1.30 and a debt-to-equity ratio of 0.12. The firm has a market capitalization of $1.27 million, a P/E ratio of -0.03 and a beta of 2.05.
Institutional Investors Weigh In On Scinai Immunotherapeutics
An institutional investor recently raised its position in Scinai Immunotherapeutics stock. Citadel Advisors LLC grew its holdings in shares of Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI – Free Report) by 146.8% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 28,630 shares of the company’s stock after acquiring an additional 17,031 shares during the period. Citadel Advisors LLC owned about 0.90% of Scinai Immunotherapeutics worth $36,000 as of its most recent SEC filing. 58.41% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
Get Our Latest Research Report on Scinai Immunotherapeutics
Scinai Immunotherapeutics Company Profile
Scinai Immunotherapeutics Inc is a clinical-stage biotechnology company dedicated to developing novel small-molecule therapies that enhance the immune system’s capacity to recognize and destroy cancer cells. The company’s research emphasizes checkpoint modulation and the discovery of compounds designed to work in concert with established immuno-oncology treatments across a range of solid tumors.
Scinai’s pipeline comprises preclinical and early-stage candidates, and the company relies on collaborations with academic institutions and contract research organizations to advance its discovery and development efforts.
Featured Articles
- Five stocks we like better than Scinai Immunotherapeutics
- FuelCell Energy Just Got a Wake-Up Call From Wall Street
- Short Sellers Are Piling Into Wingstop, But Analysts See Big Upside
- Synchrony’s Comeback Is Hiding in Plain Sight
- Uranium Energy Corp Melts Down—Nuclear Opportunity at Hand
Receive News & Ratings for Scinai Immunotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scinai Immunotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
